BridgeBio Pharma (BBIO) Stock Price, News & Analysis

$29.75
-0.34 (-1.13%)
(As of 12:16 PM ET)
Today's Range
$29.48
$30.33
50-Day Range
$24.33
$31.04
52-Week Range
$12.75
$44.32
Volume
365,144 shs
Average Volume
1.69 million shs
Market Capitalization
$5.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

BridgeBio Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
60.0% Upside
$47.67 Price Target
Short Interest
Bearish
11.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
0.61mentions of BridgeBio Pharma in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$85,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.24) to ($2.57) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.63 out of 5 stars

Medical Sector

83rd out of 918 stocks

Pharmaceutical Preparations Industry

29th out of 429 stocks

BBIO stock logo

About BridgeBio Pharma Stock (NASDAQ:BBIO)

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Stock Price History

BBIO Stock News Headlines

Promising Clinical Data Bolsters Buy Rating for BridgeBio Pharma
BridgeBio Pharma: Q1 Earnings Snapshot
BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma, Inc. (BBIO)
See More Headlines
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
5/19/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
550
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.00
High Stock Price Target
$70.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+59.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-643,200,000.00
Net Margins
-246.24%
Pretax Margin
-250.09%

Debt

Sales & Book Value

Annual Sales
$9.30 million
Book Value
($5.54) per share

Miscellaneous

Free Float
133,760,000
Market Cap
$5.63 billion
Optionable
Optionable
Beta
1.08
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Neil Kumar Ph.D. (Age 45)
    Co-Founder, President, CEO & Director
    Comp: $2.1M
  • Dr. Charles J. Homcy M.D. (Age 76)
    Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
    Comp: $208k
  • Dr. Brian C. Stephenson C.F.A. (Age 43)
    Ph.D., CFO & Secretary
    Comp: $1.15M
  • Dr. Richard H. Scheller Ph.D. (Age 71)
    Chairman of Research & Development
    Comp: $202.4k
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Co-Founder, Chairman of Oncology & Director
  • Dr. Uma Sinha Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $1.31M
  • Grace Rauh
    Vice President of Communications
  • Mr. Eli M. Wallace Ph.D. (Age 57)
    Chief Scientific Officer of Oncology
  • Dr. Thomas Trimarchi Ph.D.
    Chief Product Officer
  • Dr. Eric Michael David J.D. (Age 52)
    M.D., Ph.D., Chief Executive Officer of Gene Therapy

BBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BBIO shares.
View BBIO analyst ratings
or view top-rated stocks.

What is BridgeBio Pharma's stock price target for 2024?

11 analysts have issued 12-month price targets for BridgeBio Pharma's stock. Their BBIO share price targets range from $33.00 to $70.00. On average, they expect the company's share price to reach $47.67 in the next twelve months. This suggests a possible upside of 60.0% from the stock's current price.
View analysts price targets for BBIO
or view top-rated stocks among Wall Street analysts.

How have BBIO shares performed in 2024?

BridgeBio Pharma's stock was trading at $40.37 at the beginning of 2024. Since then, BBIO shares have decreased by 26.2% and is now trading at $29.79.
View the best growth stocks for 2024 here
.

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our BBIO earnings forecast
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted its earnings results on Thursday, February, 22nd. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.87) by $0.09. The business earned $1.74 million during the quarter, compared to the consensus estimate of $4.78 million. BridgeBio Pharma's revenue for the quarter was down 8.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.92) earnings per share.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.07%), Janus Henderson Group PLC (1.77%), Capital Research Global Investors (1.18%), Hhlr Advisors LTD. (0.73%), Principal Financial Group Inc. (0.57%) and Price T Rowe Associates Inc. MD (0.43%). Insiders that own company stock include Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BBIO) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners